All News

A predictive model that incorporates the androgen receptor concentration of prostate cancer cells can identify patients who have an increased risk of clinical failure 5 years after radical prostatectomy.

Recent research suggests that the common fusion of two genes may point to a molecular basis for prostate cancer.

Epidemiologic studies show that prostate cancer does not occur at the same rate all over the world.

Researchers at Johns Hopkins have made significant progress on the development of a new serum biomarker known as Early Prostate Cancer Antigen-2.

Products and services from manufacturers who are exhibiting at the American Urological Association meeting in Anaheim.

Those in town for AUA 2007 will be delighted to learn that Anaheim, heavily vested in tourism, offers a vast collection of culinary options to satisfy even the most discriminating appetite.

Once known as the strawberry-growing capital of the United States, the area is cultivating a new field as a vacation destination, with something for every age and every interest, from scuba and baseball, to shopping and wine tours, to amusement parks, theater, and concerts, all within Anaheim proper or a short drive from the city.

The treatment of metastatic renal cell carcinoma has undergone significant changes.

Androgen deprivation therapy's documented adverse effects on cardiac risk factors might translate into an increased risk of cardiac mortality for older prostate cancer patients.

A predictive model that incorporates the androgen receptor concentration of prostate cancer cells can identify patients who have an increased risk of clinical failure 5 years after radical prostatectomy.

New research findings have provided further evidence that 5-alpha-reductase inhibitors may play a role in preventing prostate cancer.

The dilemma surrounding the value of widespread PSA screening for early detection of prostate cancer remains unresolved.

A virus that is known to cause leukemia in mice, xenotropic murine leukemia-related virus (XMRV), also may be responsible for prostate cancer in humans.

A single PSA value measured in men between 44 and 50 years of age is highly predictive of the development of clinically diagnosed prostate cancer up to 25 years later.

Updated life expectancy tables, text on surveillance, treatment failure, and ADT validate diverse therapeutic approaches to prostate cancer.

A new biomarker, which is under investigation at Johns Hopkins, shows great potential to address both of these controversial issues.

As a practicing urologist and former journal editor, Jerry G. Blaivas, MD, has confronted many ethical issues facing urologists today.

Many patients, practices, and hospitals are having a difficult time finding a urologist this year, and that difficulty is going to grow as the next 2 decades tick past.

images

images

images

FDA Commissioner Andrew C. von Eschenbach, MD, recently received the American Association for Cancer Research Distinguished Service Award for exemplary leadership as director of the National Cancer Institute during a time of flourishing scientific and technological advances with gradually diminishing resources.

The Cleveland Clinic has announced the creation of a new institute combining the hospital's urology and nephrology programs. Andrew C. Novick, MD, will serve as chairman of the newly formed Glickman Urological and Kidney Institute.

FDA Commissioner Andrew C. von Eschenbach, MD, recently received the American Association for Cancer Research Distinguished Service Award for exemplary leadership as director of the National Cancer Institute during a time of flourishing scientific and technological advances with gradually diminishing resources.

Men who have survived for at least 1 year after being diagnosed with testicular cancer have a slightly higher risk of dying from non-cancer causes-including infections, digestive diseases, and circulatory diseases-than the general population does, a study published in the Journal of the National Cancer Institute (2007; 99:533-44) suggests. Men treated with chemotherapy in 1975 or later may be at particularly high risk.

Abuse history, other major trauma, and post-traumatic stress disorder are reported commonly in women with chronic pelvic pain, suggesting the importance of screening for post-traumatic stress disorder in these women, according to researchers at the University of North Carolina at Chapel Hill.

The stress hormone epinephrine causes changes in prostate cancer cells that may make them resistant to cell death, scientists at Wake Forest University School of Medicine, Winston-Salem, NC, report.

In prostate cancer patients receiving a gonadotropin-releasing hormone agonist, a single treatment with the bisphosphonate zoledronic acid (Zometa) significantly increases bone mineral density, according to researchers at Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston.

PSA doubling time appears to be a reliable tool to distinguish which patients have prolonged innocuous PSA levels after therapy from those who are at great risk for disease recurrence and death from prostate cancer, according to researchers from the Mayo Clinic in Rochester, MN.

The American Society of Clinical Oncology has updated its 2004 clinical practice guidelines for the initial management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer.